1
Home
Companies

Mersana Therapeutics

#9572

Rank

$45.35M

Marketcap

US United States

Country

Mersana Therapeutics
Leadership team

Ms. Anna Protopapas M.B.A. (Pres, CEO & Director)

Mr. Brian C. DeSchuytner (Sr. VP & CFO)

Dr. Timothy B. Lowinger Ph.D. (Chief Science & Technology Officer)

Products/ Services
Biotechnology, Health Care, Medical, Therapeutics
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2005
Company Registration
SEC CIK number: 0001442836
Revenue
5M - 20M
Traded as
MRSN
Social Media
URL
https://www.mersana.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
History

Mersana Therapeutics was founded in Cambridge, Massachusetts in 2011 and is a clinical-stage biopharmaceutical company dedicated to transforming the lives of cancer patients through its differentiated, in-house designed ADC platform, Fleximer. It has raised $347 million in Series C funding in June 2020 and is developing antibody-drug conjugate therapies for solid tumors and hematologic malignancies.

Mission
To deliver innovative, safe and effective antibody drug conjugate therapies for the benefit of cancer patients worldwide.
Vision
To be at the forefront of the next generation of innovative cancer therapies.
Key Team

Mr. Jason Fredette (Sr. VP of Investor Relations & Corp. Communications)

Ms. Alejandra Veronica Carvajal J.D. (SVP, Sec. & Chief Legal Officer)

Ms. Carla Poulson (Chief People Officer)

Dr. Tushar Misra Ph.D. (SVP & Chief Manufacturing Officer)

Mr. Chuck Miller (Sr. VP of Regulatory Affairs)

Mr. Mikhail Papisov Ph.D. (Co-Founder)

Mr. Ashish Mandelia (VP, Controller & Principal Accounting Officer)

Recognition and Awards
Mersana Therapeutics has been recognized for its innovation and impact on patient care by several organizations including, Edison Award, Ernst and Young Entreprenuer Of The Year, The BIO International Innovation Award, and more.
References

https://in.investing.com/equities/mersana-therapeutics-inc

https://www.comparably.com/companies/vision/mission

https://www.crunchbase.com/organization/mersana-therapeutics

https://finance.yahoo.com/quote/MRSN/

https://www.mersana.com

https://sec.report/CIK/0001442836

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Mersana Therapeutics
Leadership team

Ms. Anna Protopapas M.B.A. (Pres, CEO & Director)

Mr. Brian C. DeSchuytner (Sr. VP & CFO)

Dr. Timothy B. Lowinger Ph.D. (Chief Science & Technology Officer)

Products/ Services
Biotechnology, Health Care, Medical, Therapeutics
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2005
Company Registration
SEC CIK number: 0001442836
Revenue
5M - 20M
Traded as
MRSN
Social Media
URL
https://www.mersana.com